COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-12

Study Completion Date

2017-11-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed as a proof of concept, single-center, randomized, double-blind, placebo controlled study to assess the safety and efficacy of Comboprofen (Ibuprofen + Magnesium + Vitamin C) compared to placebo, Ibuprofen, Magnesium and Vitamin C monotherapies in the treatment of Delayed Onset Muscle Soreness (DOMS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

NCT02339129

Delayed Onset Muscle Soreness

COMPLETED PHASE2

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

NCT02597634

Delayed Onset Muscle Soreness, DOMS

COMPLETED PHASE3

A Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness

NCT02113566

Delayed Onset Muscle Soreness

COMPLETED PHASE4

Ibuprofen Versus Placebo For Muscle Soreness

NCT03228992

Muscle Soreness

COMPLETED PHASE4

Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS

NCT03852459

Pain, Acute

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is designed as a proof of concept, single-center, randomized, double-blind, placebo controlled study to assess the safety and efficacy of Comboprofen (Ibuprofen + Magnesium + Vitamin C) compared to placebo, Ibuprofen, Magnesium and Vitamin C monotherapies in the treatment of Delayed Onset Muscle Soreness (DOMS).

Healthy volunteers will be recruited to undergo a controlled exercise test designed to induce DOMS in lower limbs. Subjets reporting sufficient pain intensity while walking in an 11-point Numerical Rating Scale (NRS) 24h or 48 h after exercise will be randomized to receive treatment with Comboprofen, placebo, ibuprofen, magnesium or vitamin c three times a day (TID) for 3 days.

Once a subject is randomized the duration of participation will be 7 days. Subjects will be housed in the clinic for the first 24 hours of dosing. Pain intensity while standing up and sitting down and while walking will be assessed throughout the study using an 11-point (0-10) Numeric Rating Scale (NRS). Maximal isometric force, muscle damage and inflammatory markers will be also assessed throughout the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delayed Onset Muscle Soreness, DOMS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Comboprofen

Triple combination of Ibuprofen, Magnesium and Vitamin C.

Group Type EXPERIMENTAL

Comboprofen

Intervention Type DRUG

Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Powder for oral solution administered TID for 3 days

Ibuprofen

Group Type ACTIVE_COMPARATOR

Ibuprofen

Intervention Type DRUG

Powder for oral solution administered TID for 3 days

Magnesium

Group Type ACTIVE_COMPARATOR

Magnesium

Intervention Type DRUG

Powder for oral solution administered TID for 3 days

Vitamin C

Group Type ACTIVE_COMPARATOR

Vitamin C

Intervention Type DRUG

Powder for oral solution administered TID for 3 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Comboprofen

Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days

Intervention Type DRUG

Placebo

Powder for oral solution administered TID for 3 days

Intervention Type DRUG

Ibuprofen

Powder for oral solution administered TID for 3 days

Intervention Type DRUG

Magnesium

Powder for oral solution administered TID for 3 days

Intervention Type DRUG

Vitamin C

Powder for oral solution administered TID for 3 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male subjects, 18-45 years (inclusive) of age at the time of enrolment.
2. Body weight within normal range (Quetelet's index between 19 and 30) expressed as weight (kg) / height (m2).
3. Normal clinical records and physical examination.
4. No known musculoskeletal pathology.
5. Laboratory tests (hematology and biochemistry) within the range of normal values, according to the Biochemistry laboratory reference values of the 'Hospital de la Santa Creu i Sant Pau'. Variations may be admitted according to the clinical criteria of the CIM (Centre d'Investigació de Medicaments)-Sant Pau.
6. Clinically acceptable temperature, blood pressure and pulse rate in supine and standing position (SBP (Systolic blood pressure) between 100-140 mm Hg/ DBP (Diastolic blood pressure) between 50-90 mm Hg / Heart rate between 50-100 bpm). Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.
7. To be able to understand the nature of the study and comply with all their requirements.
8. Free acceptance to participate in the study by obtaining signed informed consent form approved by the CREC (Clinical Research Ethic Committee).
9. Not engaged in regular lower extremity fitness activities for more than 2 times per week for ≥ 2 consecutive weeks in the past 6 months before screening.

Exclusion Criteria

1. History of alcohol dependence or drug abuse in the last 1 year or daily consumption of alcohol \> 40 g/day for men or 24 g/day for women.
2. Heavy consumer of stimulating beverages (\>5 coffees, teas, chocolate or cola drinks per day) and grapefruit juice.
3. Background of allergy, idiosyncrasy or hypersensitivity to drugs.
4. Intake of any medication within 4 days prior to induction of DOMS that could interfere with pain or muscle function, including over-the-counter products (including natural food supplements, vitamins and medicinal plants products), any source of Magnesium and Vitamin C and ionic and protein supplements.
5. Positive serology for hepatitis B, C or HIV.
6. Background or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological or neurological disease or other chronic diseases.
7. Twelve lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc ≥ 440 msec, bradycardia (\<50 bpm) or clinically significant minor ST wave changes or any other abnormal changes on the screening ECG that would interfere with measurement of the QT interval.
8. Having undergone major surgery during the previous 6 months.
9. Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc.) from 6 months prior to drug administration.
10. Participation in another clinical trial during the 3 months preceding the drug administration.
11. Donation of blood during the 4 weeks preceding the drug administration.
12. Acute illness four weeks before drug administration.
13. Clinically significant abnormal laboratory values (as determined by the PI) at the screening evaluation.
14. Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract
15. Positive results of the drugs at screening period, at visit 2 before starting induction of DOMS or at visit 3 before starting treatment. A minimum list of 6 drugs will be screened for inclusion: Amphetamines, Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be repeated at the discretion of the PI).
16. Subjects who have been engaged in regular lower extremity fitness activities within 4 days prior to visit 2 (induction of DOMS).

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes